Cancer treatments

Oncology specialist review and treatment coordination.

A professional oncology information center for selected cancer diagnoses, with condition-specific file requirements, clinical review criteria and physician-led coordination before any travel or treatment decision.

Medical file reviewPhysician-led evaluationCoordination before travel

Start medical review View cancer areas

Medical disclaimer: These pages inform and organize the review process. They do not diagnose, prescribe or guarantee results.

Specialist-led clinical file review — **Professional medical-file preparation.**Patients receive clear document guidance before any travel or treatment decision.

Oncology evaluation directory

Selected oncology specialist review and coordination areas.

Organized by diagnosis type, so every patient file starts with the right medical records, specialist context and coordination path.

Thoracic & gastrointestinal oncology

Diagnosis pages for cancers where staging, pathology, imaging and treatment history must be reviewed together.

Non-small Cell Lung CancerHistology, stage, biomarkers Esophageal CancerEndoscopy, nutrition, staging Colon CancerColonoscopy, CEA, molecular profile Rectal CancerPelvic MRI, prior chemoradiation Pancreatic CancerProtocol imaging, CA 19-9 trend Liver CancerLiver function, AFP, viral context

Breast & gynecologic oncology

Structured coordination for pathology subtype, receptor status, stage, prior therapy and current disease status.

Breast CancerSubtype, receptor profile, tolerance Cervical CancerFIGO stage, HPV context, imaging Uterine CancerPathology subtype, surgical status

Urologic, renal & endocrine tumors

Evaluation pages focused on organ function, pathology, metastatic context and previous systemic treatment.

Prostate CancerPSA trend, Gleason/ISUP, imaging Kidney CancerRenal function, histology, sites Bladder CancerTURBT, cystoscopy, invasion status Adrenal CancerHormone activity, surgical status

Head-neck, skin & neuro-oncology

Pages for complex cases where functional status, lesion documentation and previous local treatments are essential.

Head and Neck CancersAirway, swallowing, radiotherapy history Skin CancerDermatopathology, margins, staging Brain TumorMRI quality, pathology, symptoms

Cuban biotechnology

Cuba-related products in oncology: for what, and on what evidence?

The list below is not a treatment recommendation; it summarises which product has been studied in which area.

Cuba has invested in biotechnology for many years and has developed several products used in oncology. In non-small cell lung cancer, CIMAvax-EGF and Vaxira (racotumomab) have been studied as therapeutic vaccines; nimotuzumab (CIMAher), an EGFR-directed monoclonal antibody, has been studied in head and neck, oesophageal, brain, pancreatic and cervical tumours; and HeberFERON, combining alpha and gamma interferon, has been studied in skin tumours.

What these products share is that they report encouraging results in specific indications and are licensed in Cuba within their own approved indications. Many of the published trials were conducted in defined patient groups. The right question for every patient is therefore: for my diagnosis, stage and molecular profile, what evidence supports this option?

Clarity is also needed about products with weak evidence. Vidatox, derived from blue scorpion venom and classified as homeopathic, has no reliable clinical evidence of efficacy in cancer treatment and should not be used in place of standard therapy. Equally, no supportive product replaces proven oncological treatment.

Standard therapy first

Surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy are assessed first; Cuba-related options are considered after that assessment.

Molecular profile

Markers such as EGFR, ALK, HER2 and PD-L1 directly determine which treatment can work and must be present in the file.

Ask for the evidence

For every option proposed, ask in writing which study, in which patient group, showed which outcome.

Official product information

Vidatox 30 CH: what it is officially approved for

The data below are taken from the product summary approved by CECMED, the Cuban medicines regulator. They describe the product as licensed in Cuba and are not a treatment recommendation.

Registration: Sanitary registration H-11-038-N02, registered 15 March 2011
Classification: Homeopathic medicine, 30 CH dilution, prepared from the venom of the scorpion Rhopalurus junceus. Manufactured at the LABIOFAM homeopathy laboratory, Cienfuegos, Cuba.
Approved use: Complementary therapy for the relief of symptoms caused by the effects of cancer, and for pain relief. It is not approved as an antitumour treatment and does not replace oncological therapy.
Route and schedule: Five sublingual drops every 12 hours. Nothing should be eaten, drunk or smoked, and teeth should not be brushed, for 15–30 minutes before and after each dose.
Contraindications: Hypersensitivity to the medicine or its components; children under one year of age. Precautions in pregnancy and breastfeeding.

Approval in Cuba does not mean approval in your country, and it does not mean the product is suitable for you. Eligibility is decided by the physician who reviews your complete file.

Start with the file

Submit documents before making a travel or treatment decision.

A coordinator will organize the information and guide the next step according to specialist review.

Start medical review Email Team